Ascletis said oral small-molecule amylin receptor agonist candidate ASC39 showed an EC50 of 21.4 pM for the human amylin 1 receptor, versus 21.2 pM for eloralintide. In the same assay, ASC39 had an EC50 of 846.1 pM for the human calcitonin receptor, compared with 1,350.8 pM for eloralintide. In a diet-induced obese rat study, ASC39 achieved 6.6% placebo-adjusted weight loss after once-daily oral dosing for six days, versus 5.6% for eloralintide. Vehicle-treated obese rats showed a 0.6% total body weight change from baseline over the same period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260317-12055587), on March 17, 2026, and is solely responsible for the information contained therein.